Compare ADMA Biologics Inc (ADMA) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Bath & Body Works Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Bath & Body Works Inc trades at $18.99 (market cap $3.89B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 4.14% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BBWI | |
|---|---|---|
Market Cap | $2.18B | $3.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $31.87 |
52-Week Low | $7.60 | $14.85 |
Enterprise Value | $2.25B | $7.79B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
BBWI trades at $20.36, up 1.09% daily, with a bearish technical signal but strong fundamentals including a low P/E of 5.78 and net income margin of 10.03%. Recent earnings show mixed beats, while cash flow trends improved in 2026 forecasts. The company expands globally via Ulta Beauty partnerships and Brazil entry, supporting growth narratives amid revenue declines from $7.9B in 2022 to $7.3B in 2025.
Outlook balances deep value with execution risks; analyst consensus price target of $22.11 implies upside, but high debt and revenue pressures require monitoring turnaround initiatives. Opportunities lie in margin strength and expansion, while risks include competitive retail headwinds and liability management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
